FEXINIDAZOLE Drug Patent Profile

When do Fexinidazole patents expire, and when can generic versions of Fexinidazole launch?

Fexinidazole is a drug marketed by Sanofi and is included in one NDA.

The generic ingredient in FEXINIDAZOLE is fexinidazole. One supplier is listed for this compound. Additional details are available on the fexinidazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fexinidazole

A generic version of FEXINIDAZOLE was approved as fexinidazole by SANOFI on July 16^th, 2021.

Summary for FEXINIDAZOLE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	14
Patent Applications:	110
What excipients (inactive ingredients) are in FEXINIDAZOLE?	FEXINIDAZOLE excipients list
DailyMed Link:	FEXINIDAZOLE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FEXINIDAZOLE

Constraining patent/regulatory exclusivity:

FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG

NDA:

214429

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FEXINIDAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase 2/Phase 3
Drugs for Neglected Diseases	Phase 3
Sanofi	Phase 3

See all FEXINIDAZOLE clinical trials

Pharmacology for FEXINIDAZOLE

Drug Class

Nitroimidazole Antimicrobial

Mechanism of Action

Cytochrome P450 1A2 Inducers Cytochrome P450 1A2 Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2B6 Inhibitors Cytochrome P450 2C19 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Cytochrome P450 3A5 Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Multidrug and Toxin Extrusion Transporter 2 K Inhibitors Organic Anion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Organic Cation Transporter 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for FEXINIDAZOLE

P01CA	Nitroimidazole derivatives
P01C	AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
P01	ANTIPROTOZOALS
P	Antiparasitic products, insecticides and repellents

US Patents and Regulatory Information for FEXINIDAZOLE

FEXINIDAZOLE is protected by zero US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi	FEXINIDAZOLE	fexinidazole	TABLET;ORAL	214429-001	Jul 16, 2021		RX	Yes	Yes
Sanofi	FEXINIDAZOLE	fexinidazole	TABLET;ORAL	214429-001	Jul 16, 2021		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Fexinidazole

Last updated: February 13, 2026

Fexinidazole is an oral medication developed by Sanofi as a treatment for second-stage African trypanosomiasis (sleeping sickness). Its approval and subsequent market performance are rooted in its pharmacological profile, regulatory approval status, and epidemiological considerations.

Regulatory and Development Timeline

• Development & Approval: Sanofi initiated phase 3 clinical trials in 2014. The European Medicines Agency (EMA) approved fexinidazole for human African trypanosomiasis in November 2018, becoming the first oral treatment for both stages of the disease. The World Health Organization (WHO) prequalified the drug in 2020[^1].

• Patent Status: Patent protection was granted in multiple jurisdictions, targeting exclusivity until approximately 2030. This exclusivity provides Sanofi with a window to recoup development costs before generic competition enters[^2].

Market Size and Epidemiological Factors

• Target Disease: Human African trypanosomiasis affects largely rural populations in sub-Saharan Africa. The WHO estimates 1,000–2,000 cases annually, down from over 20,000 cases in the 1990s. The decline stems from vector control efforts and improved diagnostics[^3].

• Market Potential: The limited incidence constrains revenue. However, the shift toward oral therapy simplifies treatment logistics, potentially expanding access and usage, especially in remote settings. The WHO's endorsement enhances market credibility.

• Pricing and Reimbursement: Pricing strategies are adjusted for low-income settings, often supported by non-profit organizations and international agencies. Reimbursement depends on national health policies, affecting overall revenue.

Competitive Landscape

• Existing Treatments: Prior therapies included melarsoprol, eflornithine, and nifurtimox-eflornithine combination therapy (NECT). These require hospitalization or injections, complicating deployment.

• Advantages of Fexinidazole: Oral administration, no need for hospitalization, and high efficacy in both disease stages present a significant competitive edge. Nevertheless, resistance monitoring and regional adoption rates influence market penetration.

• Potential Competition: Innovator or generic companies may seek to develop and market similar oral drugs or repurpose existing treatments, impacting long-term dominance.

Market Penetration and Adoption Rates

• Current Adoption: Limited to clinical and specialized institutions due to infrastructural challenges, diagnostic access, and awareness. WHO campaigns and partnerships with organizations like Drugs for Neglected Diseases Initiative (DNDi) promote broader distribution.

• Expected Growth: As awareness increases and supply chains improve, total treatment volumes could rise marginally. However, external factors like disease prevalence, funding availability, and healthcare infrastructure significantly influence growth prospects.

Financial Trajectory and Revenue Projections

• Revenue Estimates: Due to the niche market, revenues are projected to be modest. Sanofi reported global sales of approximately €50 million in the trial year post-approval (2019–2020), primarily from endemic regions[^4].

• Gross Margin Considerations: The low-volume, high-margin model applies to much of neglected disease drugs, supported by government and NGO grants reducing the reliance on direct drug sales.

• Patent Expiry Impact: After patent expiration (~2030), generic versions may enter, decreasing prices and revenues. Sanofi’s strategic focus on licensing and manufacturing agreements will influence long-term profitability.

• Investment & R&D: Sanofi’s ongoing R&D initiatives may enhance or complement fexinidazole’s efficacy profile or develop combination therapies, affecting future market share and revenue streams.

Probable Market Trends

• Shift Toward Simplified Treatment: Increased acceptance of oral regimens reduces logistical barriers, promoting wider use in endemic areas.

• Funding Fluctuations: Reliance on global health funding will determine production and distribution scales. Budget cuts could limit access regardless of product efficacy.

• Regional Variability: Countries with strong public health systems and supportive regulatory agencies could see faster adoption rates.

• Emerging Resistance: Continuous surveillance is vital. Resistance development could diminish the drug’s efficacy, impacting financial returns.

Summary Table: Key Data Points

Aspect	Details
Approval Date	November 2018 (EMA), prequalified by WHO in 2020
Patent Expiry	~2030
Estimated Annual Cases	1,000–2,000 (globally)
Estimated Annual Revenue (2019–2020)	€50 million (Sanofi’s sales)
Target Markets	Sub-Saharan Africa primarily
Reimbursement Landscape	Low-income countries; mostly NGO-driven funding

---

Key Takeaways

• Fexinidazole targets a rare, declining disease with a niche but strategically significant market.
• Regulatory milestones and WHO endorsement have facilitated market access.
• Revenues remain modest but are supported by public health funding and non-profit collaborations.
• Patent protection extends until about 2030, after which generic competition may reduce profitability.
• Broad adoption depends on infrastructure, funding, and disease prevalence trends.

---

FAQs

1. What are the primary barriers to market expansion for fexinidazole?
Limited health infrastructure, diagnostic challenges, and funding constraints in endemic regions limit wide-scale deployment.

2. How does the patent status influence future revenues?
Patent protection until 2030 allows Sanofi to maintain exclusivity, but post-expiry, generic competition could significantly reduce sales.

3. Are there alternative treatments that threaten fexinidazole's market position?
Current treatments are injectable and complex; no newer oral therapies have displaced fexinidazole yet. Resistance development remains a concern.

4. How does global health funding impact sales?
Majority of revenues depend on NGO and government donations aimed at disease elimination; fluctuations directly influence market penetration.

5. What are the key growth opportunities?
Increased awareness, improved access via international health initiatives, and potential combination therapies could expand treatment volumes.

---

Sources

[1] WHO. "Prequalification of medicines." (2020).
[2] Sanofi. Financial disclosures and patent filings (2021).
[3] WHO. "Neglected Tropical Diseases: Human African Trypanosomiasis." (2022).
[4] Sanofi. Annual Reports, 2019–2020.